Skip to main content
. 2014 Jul 11;15(1):78. doi: 10.1186/1465-9921-15-78

Figure 3.

Figure 3

On-treatment AEs and SAEs. On-treatment AEs reported by ≥4% of patients in any treatment group and SAEs reported by ≥1% of patients in any treatment group in the ITT population. AE, adverse event; COPD, chronic obstructive pulmonary disease; ITT, intent-to-treat; SAE, serious AE; UMEC, umeclidinium; VI, vilanterol. Patient numbers are indicated above bars.